S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office

Cosmos Holdings May be a Long-Term Buy with Short-Term Risk

Key Points

  • COSM stock is up 618% in November, likely due to a short squeeze. 
  • The company does have an appealing business model and may be genuinely undervalued. 
  • But, investors need to weigh a high level of short interest along with the high probability of a reverse stock split in the near future. 
  • Long-term investors may want to wait for more clarity on the board’s actions before taking a position.  

     

  • 5 stocks we like better than Cosmos Health
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk

Shares of Cosmos Holdings (NASDAQ: COSM) stock are up 618% in November. This penny stock has gone from trading for actual pennies per share to 68 cents per share at the time of this writing. The company has had some favorable news to report. But this has all the earmarks of a short squeeze. 

Price movement like what’s happening with COSM stock can attract a lot of investors. Just look at what happened to stocks such as GameStop (NYSE: GME) and AMC Entertainment (NYSE: AMC) in 2021. But what comes up sharply can also drop at the same rate. In this article, we’ll look at why Cosmos Holdings may be worth your investment and where the risks lie. 

Serving Two Growing Markets

Cosmos Holdings is a vertically integrated pharmaceutical company. The company has its own proprietary line of nutraceuticals that it sells through several of its subsidiaries. It also distributes a broad line of branded generic drugs and OTC pharmaceuticals that have lost patent protection.  

According to its October 2022 corporate presentation, the company partners with several of the world’s leading pharmaceutical companies including Pfizer (NYSE: PFE), GSK (NYSE: GSK), and AstraZeneca (NASDAQ: AZN).  


Demand for pharmaceuticals will continue to remain strong with an aging population and the continued search for treatments for diseases such as diabetes and cancer. But investors should also pay attention to the neutraceutical side of the business. According to the company, the global neutraceuticals market is expected to reach $988 billion by 2030; up from $455 billion in 2021. That’s a compound annual growth rate of 9%.  

One reason for this is the Covid-19 pandemic which has caused people to reassess their personal health. For an increasing number that means considering products, like dietary supplements and functional food, that they may have previously dismissed.  

To that end, on November 29, 2022 the company announced that it is now in the development phase for one of its products, CCX0722, which the company says will be “an innovative product for obesity and weight management...” COSM stock jumped 36% on just that news and, so far, is holding those gains. 

What Could Go Wrong? 

Penny stocks are attracting the attention of investors and with good reason. These “inexpensive” stocks can supply the growth that investors are looking for without having to put a lot of capital at risk.  

But many penny stocks have that designation for a reason. Many of these companies are not profitable and that’s the case with Cosmos Holdings. The company is generating revenue, but profitability seems to be some time away. 

That being said, you can make a case that COSM stock is trading below the intrinsic value of a company that has a recorded annual revenue of just over $56 million.  

But there are two notable issues. First, the amount of short interest on the stock has jumped 11.8% in the month ending November 15, 2022. That puts total short interest at over 24%. That’s a set-up for a trader, but not for an investor who is looking to take a long position.  

The second issue is that the company has received a delisting notice from the NASDAQ exchange. In a press release, the company says it is taking all the necessary steps to get into compliance. One of those steps may include a reverse stock split. The company is introducing a proposal at its annual shareholders meeting on December 2, 2022 that would give the board of directors authority to proceed with such a split to remain listed on the exchange.  

Know What You’re Buying with COSM Stock? 

Is it time for investors to climb aboard? A reverse stock split, which is looking increasingly likely, is generally not good for investors. But there is a saying you get a stock at the price you deserve. If you first bought the stock when it was priced much lower than today, your average cost basis is lower than the current share price. In that case, you’re in the money. If you believe that Cosmos Holdings can move higher, you shouldn’t be that concerned about a reverse split. 

But if you don’t currently hold shares, the best course of action is to proceed with caution. In fact, you’ll probably want the share price to come down a little from its current level.  

 

Should you invest $1,000 in Cosmos Health right now?

Before you consider Cosmos Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cosmos Health wasn't on the list.

While Cosmos Health currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
10

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Cosmos Health (COSM)
0 of 5 stars
$5.80-9.8%N/AN/AN/AN/A
GameStop (GME)
0.7481 of 5 stars
$22.25-2.0%N/A-13.28Reduce$5.30
AMC Entertainment (AMC)
1.0758 of 5 stars
$6.08flatN/A-4.44Hold$3.78
Pfizer (PFE)
3.4676 of 5 stars
$44.06-0.6%3.72%8.04Hold$52.13
GSK (GSK)
2.4048 of 5 stars
$34.83-0.9%3.76%4.06HoldN/A
AstraZeneca (AZN)
2.4042 of 5 stars
$63.44+0.5%1.43%94.69Hold$98.00
Compare These Stocks  Add These Stocks to My Watchlist 

Chris Markoch

About Chris Markoch

Contributing Author: Retirement, Individual Investing

Chris Markoch is a freelance financial copywriter with over five years of experience covering various aspects of the financial markets. You may find his writing a little different than other stock articles you’ve read. And that’s OK with him. Chris doesn’t have a traditional finance background. What he does bring to the table is a strong business and marketing background having worked for agencies that serviced Fortune 500 companies. With that in mind, he isn’t overly impressed with what companies say, and more focused on what they do. And because buyer behavior dictates so much of what happens with a stock, Chris always keeps the end consumer close in mind. Chris has been writing for MarketBeat since 2018.

Contact Chris Markoch via email at CTMarkoch@msn.com.

Featured Articles and Offers

Search Headlines: